Australia's most trusted
source of pharma news
Sunday, 05 October 2025
Posted 1 October 2025 AM
A bumper list of 21 drugs has landed at the TGA, with 10 of those under evaluation, newcomers to the Australian market.
Sanofi's BTK inhibitor Cenrifki is being evaluated for use in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS) to help slow down disability progression, after being granted priority review.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.